22O 转移性宫颈癌(CC)中生物标志物与共配伍维博单抗/pembrolizumab(维博/pembro)反应的关联:来自II期KEYVIBE-005研究的探索性分析

IF 7.1 2区 医学 Q1 ONCOLOGY ESMO Open Pub Date : 2024-06-01 DOI:10.1016/j.esmoop.2024.103522
C. Le Tourneau , C.I. Rojas , A. Leary , K. Yonemori , I. Lugowska , D. Tosi , F. Ghiringhelli , C. Caglevic , E.P. Yanez Ruiz , R. Perets , S.Y. Rha , P. Salman , T. Doi , Y. Zhang , G. Akturk , C.E. Pena , T. Keenan , Y. Chen , E. Dettman , O. Ozyilkan
{"title":"22O 转移性宫颈癌(CC)中生物标志物与共配伍维博单抗/pembrolizumab(维博/pembro)反应的关联:来自II期KEYVIBE-005研究的探索性分析","authors":"C. Le Tourneau , C.I. Rojas , A. Leary , K. Yonemori , I. Lugowska , D. Tosi , F. Ghiringhelli , C. Caglevic , E.P. Yanez Ruiz , R. Perets , S.Y. Rha , P. Salman , T. Doi , Y. Zhang , G. Akturk , C.E. Pena , T. Keenan , Y. Chen , E. Dettman , O. Ozyilkan","doi":"10.1016/j.esmoop.2024.103522","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012912/pdfft?md5=b28512bdc4047aeb09946fde3f2795a7&pid=1-s2.0-S2059702924012912-main.pdf","citationCount":"0","resultStr":"{\"title\":\"22O Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study\",\"authors\":\"C. Le Tourneau , C.I. Rojas , A. Leary , K. Yonemori , I. Lugowska , D. Tosi , F. Ghiringhelli , C. Caglevic , E.P. Yanez Ruiz , R. Perets , S.Y. Rha , P. Salman , T. Doi , Y. Zhang , G. Akturk , C.E. Pena , T. Keenan , Y. Chen , E. Dettman , O. Ozyilkan\",\"doi\":\"10.1016/j.esmoop.2024.103522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11877,\"journal\":{\"name\":\"ESMO Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2059702924012912/pdfft?md5=b28512bdc4047aeb09946fde3f2795a7&pid=1-s2.0-S2059702924012912-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2059702924012912\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702924012912","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
22O Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESMO Open
ESMO Open Medicine-Oncology
CiteScore
11.70
自引率
2.70%
发文量
255
审稿时长
10 weeks
期刊介绍: ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research. ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO. Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.
期刊最新文献
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced tumor disease PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1